Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib + Letrozole in Advanced Breast Cancer
NCT01958021Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2013
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Ribociclib + Letrozole with Placebo + Letrozole (2 arms). Primary endpoint: Progression Free Survival up to 23 months. Started Dec 2013; status: completed.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01958021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01958021.